Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study.
Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study.
复制标题
免疫疗法联合或不联合放射治疗转移性或复发性食管鳞状细胞癌：一项真实世界研究
DOI：
10.1016/j.ctro.2022.10.011
复制
发表时间：
2023-01
影响因子：
3.1
通讯作者：
中科院分区：
文献类型：
--
作者：
免疫疗法和放疗对晚期 ESCC 的疗效尚未得到充分描述。放疗免疫治疗可改善局部复发性食管鳞癌的生存率。与单独的免疫疗法相比，放疗可以更好地解决吞咽困难。评估免疫治疗联合或不联合放疗（RT）治疗转移性或复发性食管鳞状细胞癌（ESCC）的有效性和安全性。我们回顾性分析了 2017 年至 2021 年间在天津医科大学肿瘤研究所接受或不接受免疫治疗的 127 例转移性或复发性 ESCC 患者的数据。中位随访时间为 15.7 个月（95% 置信区间 (CI)：12.42–18.99）。 RT 组和 NRT 组的中位 PFS 分别为 5.45 个月（95% CI：2.89–8.28）和 4.60 个月（95% CI：3.75–7.06）（P = 0.660）。中位 OS 分别为 11.9 (95% CI: 8.61–19.2) 和 10.3 (95% CI: 7.56–15.8) 个月 (P = 0.890)。 RT 组和 NRT 组局部复发患者的中位 PFS 分别为 11.27 个月（95% CI：2.45–20.09）和 4.17 个月（95% CI：2.64–5.71）（P = 0.081）。 RT 组和 NRT 组局部复发患者的中位 OS 分别为 19.48 个月（95% CI：8.37–30.60）和 7.69 个月（95% CI：3.45–11.93）（P = 0.026）。 RT 组中 64% 的患者和 NRT 组中 30% 的患者吞咽困难得到改善 (P = 0.033)。与 NRT 组相比，除了一些血液学并发症外，RT 组未观察到治疗相关毒性显着增加。局部复发患者从免疫治疗联合放疗中获得了生存获益。免疫疗法和放疗的结合对于转移性/复发性食管鳞癌患者是安全的。与单独的免疫治疗相比，食管放疗可改善吞咽困难。
Efficacy of immunotherapy and RT for advanced ESCC is not well-described. Immunotherapy with RT improved the survival of locoregional recurrent ESCC. RT led to better resolution of dysphagia compared to immunotherapy alone. To evaluate the efficiency and safety of immunotherapy combined with or without radiotherapy (RT) for metastatic or recurrent esophageal squamous cell carcinoma (ESCC). We retrospectively reviewed data of 127 patients with metastatic or recurrent ESCC, who received immunotherapy with or without RT at Tianjin Medical University Cancer Institute between 2017 and 2021. The median follow-up time was 15.7 months (95 % confidence interval (CI): 12.42–18.99). The median PFS of the RT and NRT groups was 5.45 months (95 % CI: 2.89–8.28) and 4.60 months (95 % CI: 3.75–7.06), respectively (P = 0.660). The median OS was 11.9 (95 % CI: 8.61–19.2) and 10.3 (95 % CI: 7.56–15.8) months, respectively (P = 0.890). The median PFS of locoregional recurrence patients in the RT and NRT groups was 11.27 months (95 % CI: 2.45–20.09) and 4.17 months (95 % CI: 2.64–5.71), respectively (P = 0.081). The median OS of locoregional recurrent patients in the RT and NRT groups was 19.48 months (95 % CI: 8.37–30.60) and 7.69 months (95 % CI: 3.45–11.93), respectively (P = 0.026). 64 % of patients in the RT group and 30 % of patients in the NRT group experienced an improvement in dysphagia (P = 0.033). No significant increase in treatment-related toxicity was observed in the RT group compared with the NRT group, except for some hematological complications. Locoregional recurrent patients gained survival benefits from immunotherapy combined with RT. The combination of immunotherapy and RT was safe in metastatic/recurrent ESCC patients. RT for the esophagus leads to the improvement of dysphagia compared to immunotherapy alone.
登录
查看更多内容
放疗加卡瑞利珠单抗治疗局部晚期食管鳞状细胞癌的安全性和可行性
DOI：
10.1002/onco.13797
发表时间：
2021-07
期刊：
The oncologist
影响因子：
--
作者：
Zhang W;Yan C;Gao X;Li X;Cao F;Zhao G;Zhao J;Er P;Zhang T;Chen X;Wang Y;Jiang Y;Wang Q;Zhang B;Qian D;Wang J;Zhou D;Ren X;Yu Z;Zhao L;Yuan Z;Wang P;Pang Q
通讯作者：
Pang Q
影响因子：
3.6
作者：
Chen, Jie;Yin, Wenming;Gu, Wendong
通讯作者：
Gu, Wendong
影响因子：
3.8
作者：
Jingu K;Matsushita H;Takeda K;Umezawa R;Takahashi C;Sugawara T;Kubozono M;Abe K;Tanabe T;Shirata Y;Yamamoto T;Ishikawa Y;Nemoto K
通讯作者：
Nemoto K
影响因子：
3.2
作者：
Krug, Sebastian;Michl, Patrick
通讯作者：
Michl, Patrick
影响因子：
3.4
作者：
Kassam, Z.;Wong, R. K. S.;Davey, P.
通讯作者：
Davey, P.